Spring Mill Pharma - About the company
Spring Mill Pharma is an unfunded company based in United States, founded in 2026. It operates as a Developer of therapies targeting serious bacterial and viral infectious diseases. Spring Mill Pharma has not raised any funding yet. The company has 2749 active competitors, including 888 funded and 669 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Erasca and Tango Therapeutics.
Company Details
Developer of therapies targeting serious bacterial and viral infectious diseases. Research focuses on addressing critical unmet medical needs related to resistant bacterial infections and emerging viral pathogens. The portfolio includes programs designed to combat pathogens that pose high risks to human health.
Key Metrics
Founded Year
2026
Location
Stage
Unfunded
Ranked
3360th among 3360 competitors
Employee Count
8 as on Oct 31, 2026
Similar Companies
Sign up to download Spring Mill Pharma's company profile
Spring Mill Pharma's funding and investors
Spring Mill Pharma has not raised any funding rounds yet.
Spring Mill Pharma's founders and board of directors
Founder? Claim ProfileSpring Mill Pharma's employee count trend
Spring Mill Pharma has 8 employees as of Oct 26. Here is Spring Mill Pharma's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Spring Mill Pharma's Competitors and alternates
Top competitors of Spring Mill Pharma include Jazz Pharmaceuticals, Erasca and Tango Therapeutics. Here is the list of Top 10 competitors of Spring Mill Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd | Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 72/100 | |
3rd | Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 72/100 | |
4th | Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 72/100 | |
5th | Relay Therapeutics 2016, Cambridge (United States), Public | Developer of drug discovery platform and study protein motion | $520M | 71/100 | |
6th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
7th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 71/100 | ||
8th | Immunocore 2008, Abingdon (United Kingdom), Public | Developer of bispecific T cell receptor therapies for human diseases | $601M | 70/100 | |
9th | Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders | $69.7M | 70/100 | ||
10th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 74/100 | |
3360th | Spring Mill Pharma 2026, United States, Unfunded | Developer of therapies targeting serious bacterial and viral infectious diseases | - | - | - |
Looking for more details on Spring Mill Pharma's competitors? Click here to see the top ones
Spring Mill Pharma's Investments and acquisitions
Spring Mill Pharma has made no investments or acquisitions yet.
Reports related to Spring Mill Pharma
Here is the latest report on Spring Mill Pharma's sector:
Are you a Founder ?
FAQs about Spring Mill Pharma
Explore our recently published companies
- SPR17 SEO - Swansea based, 2026 founded, Unfunded company
- Sportsplex - India based, Unfunded company
- Spot My - Kolkata based, 2026 founded, Unfunded company
- Sports Mental Skills - Urbandale based, 2026 founded, Unfunded company
- Sports-N-Ai - Delhi based, 2026 founded, Unfunded company
- SportsKlub - Orillia based, 2026 founded, Unfunded company